FDA Advisory Committee Votes to Recommend Isis' KYNAMRO

Genzyme, a Sanofi company

, and Isis Pharmaceuticals

, announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 9 to 6 that Genzyme had provided sufficient efficacy and safety data to support the marketing of KYNAMRO™ (mipomersen sodium) for the treatment of patients with Homozygous Familial Hypercholesterolemia (HoFH). Many people with HoFH have aggressive cardiovascular disease beginning in childhood, and even with today's therapies remain at significant risk of cardiovascular events. "We are very encouraged by the support for KYNAMRO at today's Advisory Committee meeting, which marks a significant and positive step in our